1
|
Lee MF, Anasir MI, Poh CL. Serum Stabilities and Antiviral Activities of Chemically Modified Peptides Against Dengue Serotypes 1-4. J Pharm Sci 2024; 113:587-595. [PMID: 38103687 DOI: 10.1016/j.xphs.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 12/09/2023] [Accepted: 12/09/2023] [Indexed: 12/19/2023]
Abstract
Dengue presents a major public health concern in over 100 countries due to the absence of an effective vaccine and antiviral therapy against all four dengue virus (DENV) serotypes. Several antiviral peptides were previously reported to inhibit at least three or all four DENV serotypes. Chemical modifications such as d-amino acid substitutions, polyethylene glycol (PEG)ylation, and cyclization could be applied to peptides to improve their biological activities and stability in serum. The PEGylated peptide 3 (PEG-P3) was identified to be the most promising antiviral candidate as it demonstrated good inhibitory effects against all four DENV serotypes during the pre- and post-infection stages, Based on the RP-HPLC and LC/MS analysis, peptide 4 was identified to be more stable in human serum than peptide 3, with 78.9 % and 41.6 % of the peptides remaining after 72 h of incubation in human serum, respectively. Both peptides were also able to retain their antiviral activities against specific DENV serotypes after 72 h incubation in human serum. PEG-P3 was found to be more stable than the unmodified peptide 3 with 89.4 % of PEG-P3 remaining in the human serum after 72 h of incubation. PEG-P3 was able to retain its inhibitory effects against DENV-1 to 4 after 72 h of incubation in human serum. This study provided insights into the antiviral activities and stabilities of the unmodified and chemically modified peptides in human serum.
Collapse
Affiliation(s)
- Michelle Felicia Lee
- Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, 5, Jalan Universiti, Bandar Sunway, Selangor 47500, Malaysia
| | - Mohd Ishtiaq Anasir
- Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Setia Alam, Shah Alam, Selangor Malaysia
| | - Chit Laa Poh
- Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, 5, Jalan Universiti, Bandar Sunway, Selangor 47500, Malaysia.
| |
Collapse
|
2
|
Rathnam SS, Deepak T, Sahoo BN, Meena T, Singh Y, Joshi A. Metallic Nanocarriers for Therapeutic Peptides: Emerging Solutions Addressing the Delivery Challenges in Brain Ailments. J Pharmacol Exp Ther 2024; 388:39-53. [PMID: 37875308 DOI: 10.1124/jpet.123.001689] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 10/01/2023] [Accepted: 10/10/2023] [Indexed: 10/26/2023] Open
Abstract
Peptides and proteins have recently emerged as efficient therapeutic alternatives to conventional therapies. Although they emerged a few decades back, extensive exploration of various ailments or disorders began recently. The drawbacks of current chemotherapies and irradiation treatments, such as drug resistance and damage to healthy tissues, have enabled the rise of peptides in the quest for better prospects. The chemical tunability and smaller size make them easy to design selectively for target tissues. Other remarkable properties include antifungal, antiviral, anti-inflammatory, protection from hemorrhage stroke, and as therapeutic agents for gastric disorders and Alzheimer and Parkinson diseases. Despite these unmatched properties, their practical applicability is often hindered due to their weak susceptibility to enzymatic digestion, serum degradation, liver metabolism, kidney clearance, and immunogenic reactions. Several methods are adapted to increase the half-life of peptides, such as chemical modifications, fusing with Fc fragment, change in amino acid composition, and carrier-based delivery. Among these, nanocarrier-mediated encapsulation not only increases the half-life of the peptides in vivo but also aids in the targeted delivery. Despite its structural complexity, they also efficiently deliver therapeutic molecules across the blood-brain barrier. Here, in this review, we tried to emphasize the possible potentiality of metallic nanoparticles to be used as an efficient peptide delivery system against brain tumors and neurodegenerative disorders. SIGNIFICANCE STATEMENT: In this review, we have emphasized the various therapeutic applications of peptides/proteins, including antimicrobial, anticancer, anti-inflammatory, and neurodegenerative diseases. We also focused on these peptides' challenges under physiological conditions after administration. We highlighted the importance and potentiality of metallic nanocarriers in the ability to cross the blood-brain barrier, increasing the stability and half-life of peptides, their efficiency in targeting the delivery, and their diagnostic applications.
Collapse
Affiliation(s)
- Shanmuga Sharan Rathnam
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| | - Thirumalai Deepak
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| | - Badri Narayana Sahoo
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| | - Tanishq Meena
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| | - Yogesh Singh
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| | - Abhijeet Joshi
- Department of Biosciences and Biomedical Engineering (S.S.R., B.N.S., T.M., Y.S., A.J.), Indian Institute of Technology Indore, Simrol, India and Department of Biotechnology and Medical Engineering (T.D.), National Institute of Technology Rourkela, Rourkela, India
| |
Collapse
|
3
|
Abd-Aziz N, Lee MF, Ong SK, Poh CL. Antiviral activity of SP81 peptide against Enterovirus A71 (EV-A71). Virology 2024; 589:109941. [PMID: 37984152 DOI: 10.1016/j.virol.2023.109941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 10/27/2023] [Accepted: 11/09/2023] [Indexed: 11/22/2023]
Abstract
The hand, food, and mouth disease (HFMD) is primarily caused by Enterovirus A71 (EV-A71). EV-A71 outbreaks in the Asia Pacific have been associated with severe neurological disease and high fatalities. Currently, there are no FDA-approved antivirals for the treatment of EV-A71 infections. In this study, the SP81 peptide, derived from the VP1 capsid protein of EV-A71 was shown to be a promising antiviral candidate for the treatment of EV-A71 infections. SP81 peptide was non-toxic to RD cells up to 45 μM, with a half-maximal cytotoxic concentration (CC50) of 90.32 μM. SP81 peptide exerted antiviral effects during the pre- and post-infection stages with 50% inhibitory concentrations (IC50) of 4.529 μM and 1.192 μM, respectively. Direct virus inactivation of EV-A71 by the SP81 peptide was also observed with an IC50 of 8.076 μM. Additionally, the SP81 peptide exhibited direct virus inactivation of EV-A71 at 95% upon the addition of the SP81 peptide within 5 min. This study showed that the SP81 peptide exhibited significant inhibition of EV-A71 and could serve as a promising antiviral agent for further clinical development against EV-A71 infections.
Collapse
Affiliation(s)
- Noraini Abd-Aziz
- Centre for Virus and Vaccine Research (CVVR), School of Medical and Life Sciences, Sunway University, 47500, Subang Jaya, Selangor, Malaysia
| | - Michelle Felicia Lee
- Centre for Virus and Vaccine Research (CVVR), School of Medical and Life Sciences, Sunway University, 47500, Subang Jaya, Selangor, Malaysia
| | - Seng-Kai Ong
- Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, 47500, Subang Jaya, Selangor, Malaysia
| | - Chit Laa Poh
- Centre for Virus and Vaccine Research (CVVR), School of Medical and Life Sciences, Sunway University, 47500, Subang Jaya, Selangor, Malaysia.
| |
Collapse
|